| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Cardiology and Pneumology, Free University of Berlin;
* Institute of Molecular Pharmacology, Berlin, Germany; and
Institute of Pharmacology, Medical University of Lübeck, Germany
1Correspondence: University Hospital Benjamin Franklin, Department of Cardiology and Pneumology, Free University of Berlin, Hindenburgdamm 30, D-12200 Berlin Germany. E-mail: thomas.walther{at}ukbf.fu-berlin.de
ACE inhibition protects the heart against ischemic injury by reducing angiotensin II and promoting bradykinin (BK) accumulation. Since neutral endopeptidase (NEP) metabolizes BK, we determined its activity after induction of myocardial infarction (MI) and examined whether it is influenced by treatment with an ACE inhibitor or AT1 receptor blocker. Rats were studied 6 days and 3 wk after coronary occlusion. Starting 48 h after MI induction, additional animals were treated with the ACE inhibitor quinapril (2 mg·kg-1·day-1) or the AT1 blocker irbesartan (50 mg·kg-1·day-1). Animals were hemodynamically characterized. Finally, NEP-specific activity and BK concentrations were detected in homogenates of heart compartments. Quinapril and irbesartan treatment improved left ventricular function 6 days and 3 wk after MI induction, and NEP activity was elevated only in the infarcted area of untreated compared with sham-operated rats. After 6 days, irbesartan reversed this increase by 80% and quinapril by 35%. Quinapril had no effect after 3 wk, whereas irbesartan almost completely blocked the increased NEP activity in the infarcted area and concomitantly induced a further rise in the BK concentrations. These results indicate mechanisms of NEP regulation influenced by the AT1 receptor. Our data suggest that NEP is more decisive than ACE in mediating BK degradation and may indicate BK involvement in the cardioprotective effects of AT1 antagonists.—Walther, T., Siems, W.-E., Hauke, D., Spillmann, F., Dendorfer, A., Krause, W., Schultheiss, H.-P., Tschöpe, C. AT1 receptor blockade increases cardiac bradykinin via neutral endopeptidase after induction of myocardial infarction in rats.
Key Words: bradykinin • enzymes • hemodynamics • inhibitors • neutral endopeptidase • renin-angiotensin system
This article has been cited by other articles:
|
|
 |
|
  F. G. Pelorosso, A. V. Halperin, A. M. Palma, W. Nowak, A. E. Errasti, and R. P. Rothlin Neutral Endopeptidase Up-Regulation in Isolated Human Umbilical Artery: Involvement in Desensitization of Bradykinin-Induced Vasoconstrictor Effects J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 713 - 720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Gardiner, J. E. March, P. A. Kemp, S. A. Ballard, and T. Bennett Regional Hemodynamic Effects of Neutral Endopeptidase Inhibition and Angiotensin (AT1) Receptor Antagonism Alone or in Combination in Conscious Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 340 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fraccarollo, P. Galuppo, I. Schmidt, G. Ertl, and J. Bauersachs Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction Cardiovasc Res, July 1, 2005; 67(1): 97 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tschope, F. Spillmann, C. Altmann, M. Koch, D. Westermann, N. Dhayat, S. Dhayat, J.-L. Bascands, L. Gera, S. Hoffmann, et al. The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction Cardiovasc Res, February 15, 2004; 61(3): 559 - 569. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
